NeuroSense Therapeutics L...

1.16
-0.01 (-0.85%)
At close: Feb 14, 2025, 3:58 PM
undefined%
Bid 1.15
Market Cap 26.83M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.76
PE Ratio (ttm) -1.52
Forward PE n/a
Analyst Buy
Ask 1.18
Volume 67,336
Avg. Volume (20D) 286,663
Open 1.19
Previous Close 1.17
Day's Range 1.15 - 1.19
52-Week Range 0.51 - 2.33
Beta undefined

About NRSN

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC ...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 9, 2021
Employees 18
Stock Exchange NASDAQ
Ticker Symbol NRSN

Analyst Forecast

According to 1 analyst ratings, the average rating for NRSN stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 month ago
+12.28%
NeuroSense Therapeutics shares are trading higher.... Unlock content with Pro Subscription
2 months ago
+14.27%
NeuroSense Therapeutics shares are trading higher after the company announced its CEO purchased $5 million worth of ordinary shares in a private placement.